Lipidic nanocapsule drug delivery: neuronal protection for cochlear implant optimization | Zendy

Verena Scheper | Zendy; Meyer | Zendy; Stöver | Zendy; Fouchet | Zendy; Guillaume Bastiat | Zendy; Patrick Saulnier | Zendy; Baeumer | Zendy; Lenarz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lipidic nanocapsule drug delivery: neuronal protection for cochlear implant optimization

Author(s) -

Verena Scheper,

Meyer,

Stöver,

Fouchet,

Guillaume Bastiat,

Patrick Saulnier,

Baeumer,

Lenarz

Publication year - 2012

Publication title -

international journal of nanomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.245

H-Index - 128

eISSN - 1178-2013

pISSN - 1176-9114

DOI - 10.2147/ijn.s29712

Subject(s) - rolipram , in vivo , pharmacology , spiral ganglion , in vitro , perilymph , tumor necrosis factor alpha , drug delivery , chemistry , medicine , phosphodiesterase , biology , cochlea , immunology , biochemistry , anatomy , microbiology and biotechnology , enzyme , organic chemistry

Sensorineural hearing loss leads to the progressive degeneration of spiral ganglion cells (SGC). Next to postoperative fibrous tissue growth, which should be suppressed to assure a close nerve-electrode interaction, the density of healthy SGC is one factor that influences the efficiency of cochlear implants (CI), the choice of treatment for affected patients. Rolipram, a phosphodiesterase-4 inhibitor, has proven neuroprotective and anti-inflammatory effects and might also reduce SGC degeneration and fibrosis, but it has to pass the cellular membrane to be biologically active.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research